Qiu Xin, Shen Shuang, Jiang Nizhen, Feng Yifei, Yang Guodong, Lu Donghong
Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
BMC Gastroenterol. 2025 Jan 29;25(1):42. doi: 10.1186/s12876-025-03625-4.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a primary cause of chronic liver disease, with potential progression to cirrhosis and hepatocellular carcinoma (HCC). Although systemic inflammatory biomarkers are associated with liver diseases, their specific role in MASLD remains unclear. This study examines the association between systemic inflammatory biomarkers and MASLD.
This cross-sectional study enrolled 6613 adults aged 20 years or older from the National Health and Nutrition Examination Survey (NHANES) spanning from 2017 to March 2020. Among these participants,, 34.67% were aged 40-59 years, 50.85% were female, and 63.26% were Non-Hispanic White. We investigated 10 inflammatory biomarkers: ALI, SIRI, SII, SIPS, IBI, NLR, PLR, CAR, LMR, and PNI. Logistic regression models were performed to assess the linear association between systemic inflammatory biomarkers and MASLD. Restricted cubic spline (RCS) regression was employed to explore potential nonlinear relationships between biomarkers and MASLD risk. Additionally, subgroup analyses were conducted to examine the influence of various demographic and clinical characteristics on the observed associations.
After adjusting for key confounders, NLR and PLR exhibited negative association with MASLD risk, while ALI, CAR, and PNI exhibited the opposite association (P < 0.05). Most biomarkers, including ALI, SIRI, IBI, CAR, LMR, and PNI, exhibited significant non-linear correlations with MASLD (P < 0.05). Subgroup analyses revealed substantial age-related differences in the association between ALI and MASLD risk, as well as varying relationships between PNI and MASLD risk across various cardiovascular outcomes (P < 0.05).
Systemic inflammatory biomarkers are significantly associated with MASLD risk. Large-scale prospective studies are warranted to confirm these findings and elucidate the underlying mechanisms.
代谢功能障碍相关脂肪性肝病(MASLD)是慢性肝病的主要病因,有进展为肝硬化和肝细胞癌(HCC)的潜在风险。尽管全身炎症生物标志物与肝脏疾病有关,但其在MASLD中的具体作用仍不清楚。本研究探讨全身炎症生物标志物与MASLD之间的关联。
这项横断面研究纳入了6613名年龄在20岁及以上的成年人,数据来自2017年至2020年3月的美国国家健康与营养检查调查(NHANES)。在这些参与者中,34.67%的年龄在40 - 59岁之间,50.85%为女性,63.26%为非西班牙裔白人。我们研究了10种炎症生物标志物:ALI、SIRI、SII、SIPS、IBI、NLR、PLR、CAR、LMR和PNI。采用逻辑回归模型评估全身炎症生物标志物与MASLD之间的线性关联。使用限制立方样条(RCS)回归来探索生物标志物与MASLD风险之间潜在的非线性关系。此外,进行亚组分析以检查各种人口统计学和临床特征对观察到的关联的影响。
在调整关键混杂因素后,NLR和PLR与MASLD风险呈负相关,而ALI、CAR和PNI则呈现相反的关联(P < 0.05)。大多数生物标志物,包括ALI、SIRI、IBI、CAR、LMR和PNI,与MASLD呈现显著的非线性相关性(P < 0.05)。亚组分析显示,ALI与MASLD风险之间的关联存在显著的年龄相关差异,以及PNI与各种心血管结局下MASLD风险之间存在不同的关系(P < 0.05)。
全身炎症生物标志物与MASLD风险显著相关。有必要进行大规模前瞻性研究以证实这些发现并阐明潜在机制。